Seattle Genetics, Inc. (OQ:SGEN)

Business Focus: Biotechnology & Medical Research

Sector:  Healthcare Industry:  Biotechnology & Medical Research
 
See Regulatory Filings on SEC
Company Contact
Address: 21823 30th Dr SE
BOTHELL WA 98021-3907
Tel: 1-425-5274160
Website: www.seattlegenetics.com
IR: See website
<
Key People
Clay B. Siegall
Chairman of the Board, President, Chief Executive Officer
Todd E. Simpson
Chief Financial Officer
Jean I. Liu
Executive Vice President - Legal Affairs, General Counsel, Corporate Secretary
Vaughn B Himes
Chief Technical Officer
Roger Dansey
Chief Medical Officer
Brian Donnelly
Chief Commercial Officer
Robin G. Taylor
Chief Commercial Officer
   
Business Overview
Seattle Genetics, Inc. is a biotechnology company focused on the development and commercialization of therapies for the treatment of cancer. The Company is engaged in the development and sale of pharmaceutical products on its own behalf or in collaboration with others. The Company's marketed product ADCETRIS, or brentuximab vedotin, is an antibody-drug conjugate (ADC). In addition to ADCETRIS, the Company's pipeline includes other clinical-stage ADC programs, such as ASG-22ME, SGN-LIV1A, SGN-CD19A, SGN-CD19B, SGN-CD123A, SGN-352A, and ASG-15ME, as well as two immuno-oncology agents, SEA-CD40, which is based on its sugar-engineered antibody (SEA) technology, and SGN-2FF, which is a small molecule. It also has multiple preclinical and research-stage programs that employ its technologies, including SGN-CD48A and a preclinical ADC. ADCETRIS is an ADC comprising an anti-CD30 monoclonal antibody attached by a protease-cleavable linker to a microtubule disrupting agent.
Financial Overview
For the nine months ended 30 September 2019, Seattle Genetics, Inc. revenues increased 31% to $626.9M. Net loss increased 79% to $184.5M. Revenues reflect Net product sales increase of 34% to $461.6M, Collaboration and license agreement reve increase of 30% to $99.1M, Royalty revenues increase of 12% to $66.2M. Higher net loss reflects Research and development increase of 25% to $518.3M (expense), Investment and other income (loss).
Employees: 1,302 as of Dec 31, 2018
Reporting Currency: U.S. Dollars
Enterprise value: $17,811M as of Sep 30, 2019
Annual revenue (TTM): $801.42M as of Sep 30, 2019
EBITDA (TTM): -$251.31M as of Sep 30, 2019
Net annual income (TTM): -$304.29M as of Sep 30, 2019
Free cash flow (TTM): -$234.21M as of Sep 30, 2019
Net Debt Last Fiscal Year: N/A
Shares outstanding: 171,385,656 as of Oct 25, 2019
TTM: Trailing Twelve Months
EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization